You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NCI researchers performed a multi-platform study to elucidate the factors that can contribute to a patient's better-than-expected response to a drug.
The company also acquired DNA methylation analysis firm Base Genomics for $410 million and said it plans to raise $869 million in a direct stock offering.
The researchers used tumor and germline whole-genome sequencing, RNA sequencing, and methylome analysis to elucidate the molecular basis of high-risk cancers.
The deal, which was approved by the boards of directors of both companies, is expected to close in the second half of 2021, pending customary conditions.
Researchers used the methylCIBERSORT algorithm to determine the makeup of the tumor immune microenvironment of about 6,000 pediatric central nervous system tumors.
The company recently presented results from its Aurora assay for multi-cancer screening and plans to launch a $100 test for the US and Chinese markets.
Comprehensive analysis by a team led by Elaine Mardis has given 93 percent of around 150 pediatric cancer patients at least one medically actionable finding.
The INFORM study echoed the 2019 interim results from the NCI Pediatric MATCH trial, which found that 24 percent of participants were eligible for targeted treatment.
WUSTL will evaluate BostonGene's software, which integrates data from NGS with immunofluorescence imaging to profile tumors and their microenvironments.
Researchers found tumor and microenvironment features of advanced ovarian cancers respond to combination PARP inhibitor and immune checkpoint treatment.